• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食品和药物管理局对疫苗的监管和评估。

Food and Drug Administration regulation and evaluation of vaccines.

机构信息

Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, HFM 405, Rockville, MD 20850, USA.

出版信息

Pediatrics. 2011 May;127 Suppl 1:S23-30. doi: 10.1542/peds.2010-1722E. Epub 2011 Apr 18.

DOI:10.1542/peds.2010-1722E
PMID:21502242
Abstract

The vaccine-approval process in the United States is regulated by the Center for Biologics Evaluation and Research of the US Food and Drug Administration. Throughout the life cycle of development, from preclinical studies to after licensure, vaccines are subject to rigorous testing and oversight. Manufacturers must adhere to good manufacturing practices and control procedures to ensure the quality of vaccines. As mandated by Title 21 of the Code of Regulations, licensed vaccines must meet stringent criteria for safety, efficacy, and potency.

摘要

美国的疫苗审批程序由美国食品和药物管理局的生物制品评估与研究中心监管。在从临床前研究到获得许可后的整个开发生命周期中,疫苗都要经过严格的测试和监管。制造商必须遵守良好生产规范和控制程序,以确保疫苗的质量。根据法规第 21 卷的规定,许可疫苗必须符合严格的安全性、有效性和效力标准。

相似文献

1
Food and Drug Administration regulation and evaluation of vaccines.食品和药物管理局对疫苗的监管和评估。
Pediatrics. 2011 May;127 Suppl 1:S23-30. doi: 10.1542/peds.2010-1722E. Epub 2011 Apr 18.
2
Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.在食品和药物管理局,评估疫苗在整个生命周期内安全性的统计、流行病学和风险评估方法。
Pediatrics. 2011 May;127 Suppl 1:S31-8. doi: 10.1542/peds.2010-1722F. Epub 2011 Apr 18.
3
Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.确保许可疫苗的最佳安全性:疫苗研究、开发和制造公司的观点。
Pediatrics. 2011 May;127 Suppl 1:S16-22. doi: 10.1542/peds.2010-1722D. Epub 2011 Apr 18.
4
Development and approval of vaccines in the United States.
Isr J Med Sci. 1986 Mar-Apr;22(3-4):268-71.
5
Bolstering the FDA's drug-safety authority.加强美国食品药品监督管理局的药品安全监管权。
N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212.
6
Assuring the quality, safety, and efficacy of DNA vaccines.确保DNA疫苗的质量、安全性和有效性。
Mol Biotechnol. 2001 Feb;17(2):143-9. doi: 10.1385/MB:17:2:143.
7
Vaccine industry perspective of current issues of good manufacturing practices regarding product inspections and stability testing.
Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S356-61. doi: 10.1086/322573.
8
The unfinished business of U.S. drug safety regulation.美国药品安全监管的未竟之事。
Food Drug Law J. 2006;61(1):45-63.
9
Manufacturing issues with combining different antigens: a regulatory perspective.
Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S351-5. doi: 10.1086/322579.
10
Assuring the quality, safety, and efficacy of DNA vaccines.确保DNA疫苗的质量、安全性和有效性。
Methods Mol Med. 2006;127:363-74. doi: 10.1385/1-59745-168-1:363.

引用本文的文献

1
Evolution and immunopathology of chikungunya virus informs therapeutic development.基孔肯雅热病毒的进化和免疫病理学为治疗方法的开发提供了信息。
Dis Model Mech. 2023 Apr 1;16(4). doi: 10.1242/dmm.049804. Epub 2023 Apr 4.
2
Stem Cell Therapy: From Idea to Clinical Practice.干细胞治疗:从理念到临床实践。
Int J Mol Sci. 2022 Mar 5;23(5):2850. doi: 10.3390/ijms23052850.
3
Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.向欧洲联盟和美国药物警戒系统报告的 COVID-19 疫苗不良反应的频率和关联性。
Front Public Health. 2022 Feb 3;9:756633. doi: 10.3389/fpubh.2021.756633. eCollection 2021.
4
Vaccines in the United States: a systematic review on history of evolution, regulations, licensing, and future challenges.美国的疫苗:关于发展历史、法规、许可及未来挑战的系统综述
Clin Exp Vaccine Res. 2020 Jul;9(2):69-75. doi: 10.7774/cevr.2020.9.2.69. Epub 2020 Jul 31.
5
Evaluation of Newcastle Disease antibody titers in backyard poultry in Germany with a vaccination interval of twelve weeks.评价德国后院家禽的新城疫抗体滴度,其免疫间隔为 12 周。
PLoS One. 2020 Aug 25;15(8):e0238068. doi: 10.1371/journal.pone.0238068. eCollection 2020.
6
Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.当前预防寨卡病毒和基孔肯雅病毒感染疫苗的研发进展
Front Immunol. 2020 Apr 9;11:592. doi: 10.3389/fimmu.2020.00592. eCollection 2020.
7
The MMR Vaccine and Autism.麻腮风三联疫苗与自闭症。
Annu Rev Virol. 2019 Sep 29;6(1):585-600. doi: 10.1146/annurev-virology-092818-015515. Epub 2019 Apr 15.
8
Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates.在衰退疫情期间展示疫苗效力:世卫组织/美国国立卫生研究院关于开发和许可寨卡疫苗候选者方法的会议报告。
Vaccine. 2019 Feb 4;37(6):863-868. doi: 10.1016/j.vaccine.2018.12.040. Epub 2019 Jan 11.
9
Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form.认知测试,以评估疫苗不良事件报告系统(VAERS)报告表的修订情况。
Vaccine. 2017 Apr 25;35(18):2295-2297. doi: 10.1016/j.vaccine.2017.03.055. Epub 2017 Mar 25.
10
Sustaining Vaccine Confidence in the 21st Century.在21世纪维持疫苗信心。
Vaccines (Basel). 2013 Jun 24;1(3):204-24. doi: 10.3390/vaccines1030204.